Adverse Metabolic Side Effects of Second Generation Psychotropic Medications Leading to Obesity and Increased Diabetes Risk (R01)

The summary for the Adverse Metabolic Side Effects of Second Generation Psychotropic Medications Leading to Obesity and Increased Diabetes Risk (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Adverse Metabolic Side Effects of Second Generation Psychotropic Medications Leading to Obesity and Increased Diabetes Risk (R01): -Purpose. This Funding Opportunity Announcement (FOA) issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Mental Health (NIMH), National Institutes of Health (NIH), invites investigator-initiated research grant applications for studies examining the adverse metabolic effects (i.e., obesity and diabetes) of psychotropic medications in animal models and across the human lifespan (including pediatric, adult and geriatric populations). Applications responsive to this FOA should focus on 1) increasing the understanding of the nature, rates, and pathophysiology of adverse metabolic effects of psychotropic medications, 2) elucidating biomedical and psychosocial risk factors for the development of metabolic adverse effects of psychiatric therapeutics, and 3) develop interventions to prevent and/or mitigate metabolic adverse effects across the lifespan. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Federal Grant Title: Adverse Metabolic Side Effects of Second Generation Psychotropic Medications Leading to Obesity and Increased Diabetes Risk (R01)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-08-160
Type of Funding: Grant
CFDA Numbers: 93.242
CFDA Descriptions: Mental Health Research Grants
Current Application Deadline: Feb 22, 2012
Original Application Deadline: Feb 22, 2012
Posted Date: Apr 25, 2008
Creation Date: Dec 05, 2008
Archive Date: Mar 24, 2012
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants
U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (HIV/AIDS) (R01 ...
Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Tria...
Understanding the Mechanisms of Neuropsychiatric Side Effects and Neurological Toxicities ...
Pilot Services Research Grants Not Involving Clinical Trials (R34 Clinical Trial Not Allow...
Refinement and Testing of Interventions to Sustain ADHD Treatment Effects Across Settings ...
Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...
Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...
Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health
Research Project Grants in Pediatric Rehabilitation (R01 Clinical Trial Optional)
Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical ...
Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Cl...
Atopic Dermatitis Research Network Leadership Center (UM1) Clinical Trial Required
Atopic Dermatitis Research Network -Clinical Research Centers (U01 Clinical Trial Optional...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com